[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftKPAc5LL4CYa6relyLCg1M6oA_ah8aGbRDzH2XwiOkQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":53,"rows":60},"KU Leuven",[4],363,false,51,9,200248693,3,327,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Stroke",19,{"name":18,"count":19},"Chronic Obstructive Pulmonary Disease",14,{"name":21,"count":22},"Parkinson Disease",13,{"name":24,"count":25},"Healthy",11,{"name":27,"count":28},"Low Back Pain",10,{"name":30,"count":9},"Critical Illness",{"name":32,"count":33},"COPD",7,{"name":35,"count":36},"Stress",6,[38,43,48],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT00512122","Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients","2011-02","Oliclinomel N71000 OR N71000E \u002F\u002F Clinimix N17G35 OR N17G35E",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03665207","Tight Versus Liberal Blood Glucose Control in Adult Critically Ill Patients","2022-11-30","Insulin",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT07570472","The Effect of CBD on Sleep Quality Following Late Evening Exercise","2026-05-31","Cannabidiol or placebo",[54,55,56,57,58,59],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[61,86,108,131,169,196,214,240,267,285,310,336,361,389,415,441,459,487,505,530,554,578,603,629,697,724,752,770,788,806,830,852,875,905,923,941,959,977,1000,1028,1052,1070,1088,1106],{"intervention":42,"totalTrials":62,"cells":63},1,{"EARLY_PHASE1":64,"PHASE1":67,"PHASE2":69,"PHASE3":71,"PHASE4":73,"NA":84},{"trials":65,"activeCount":66},[],0,{"trials":68,"activeCount":66},[],{"trials":70,"activeCount":66},[],{"trials":72,"activeCount":66},[],{"trials":74,"activeCount":62,"soonestReadout":41},[75],{"nctId":39,"briefTitle":40,"status":76,"phases":77,"primaryCompletion":41,"completion":78,"start":79,"enrollment":80,"conditions":81,"interventions":83},"ACTIVE_NOT_RECRUITING",[58],"2026-12","2007-08",4640,[30,82],"Starvation",[42],{"trials":85,"activeCount":66},[],{"intervention":47,"totalTrials":62,"cells":87},{"EARLY_PHASE1":88,"PHASE1":90,"PHASE2":92,"PHASE3":94,"PHASE4":104,"NA":106},{"trials":89,"activeCount":66},[],{"trials":91,"activeCount":66},[],{"trials":93,"activeCount":66},[],{"trials":95,"activeCount":62,"soonestReadout":46},[96],{"nctId":44,"briefTitle":45,"status":76,"phases":97,"primaryCompletion":46,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":103},[57],"2026-11","2018-09-18",9230,[30,102],"Hyperglycemia",[47],{"trials":105,"activeCount":66},[],{"trials":107,"activeCount":66},[],{"intervention":52,"totalTrials":62,"cells":109},{"EARLY_PHASE1":110,"PHASE1":112,"PHASE2":114,"PHASE3":125,"PHASE4":127,"NA":129},{"trials":111,"activeCount":66},[],{"trials":113,"activeCount":66},[],{"trials":115,"activeCount":62,"soonestReadout":51},[116],{"nctId":49,"briefTitle":50,"status":117,"phases":118,"primaryCompletion":51,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"RECRUITING",[56],"2026-06-07","2026-03-19",20,[123],"Sleep Quality",[52],{"trials":126,"activeCount":66},[],{"trials":128,"activeCount":66},[],{"trials":130,"activeCount":66},[],{"intervention":132,"totalTrials":133,"cells":134},"Ebastine",2,{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":141,"PHASE4":143,"NA":167},{"trials":136,"activeCount":66},[],{"trials":138,"activeCount":66},[],{"trials":140,"activeCount":66},[],{"trials":142,"activeCount":66},[],{"trials":144,"activeCount":66},[145,156],{"nctId":146,"briefTitle":147,"status":148,"phases":149,"primaryCompletion":150,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":155},"NCT01908465","Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial","COMPLETED",[58],"2022-11-02","2013-11",200,[154],"Irritable Bowel Syndrome (IBS)",[132],{"nctId":157,"briefTitle":158,"status":148,"phases":159,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":165},"NCT01144832","Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists",[58],"2012-05","2009-10",55,[164],"Irritable Bowel Syndrome",[166],"ebastine",{"trials":168,"activeCount":66},[],{"intervention":170,"totalTrials":62,"cells":171},"Tiotropium + formoterol\u002Fbeclometasone",{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":194},{"trials":173,"activeCount":66},[],{"trials":175,"activeCount":66},[],{"trials":177,"activeCount":66},[],{"trials":179,"activeCount":66},[],{"trials":181,"activeCount":66},[182],{"nctId":183,"briefTitle":184,"status":185,"phases":186,"primaryCompletion":187,"completion":187,"start":188,"enrollment":121,"conditions":189,"interventions":192},"NCT01466712","Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function","UNKNOWN",[58],"2014-12","2011-11",[32,190,191],"Emphysema","Small Airway Disease",[170,193],"tiotropium + placebo",{"trials":195,"activeCount":66},[],{"intervention":193,"totalTrials":62,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":206,"NA":212},{"trials":199,"activeCount":66},[],{"trials":201,"activeCount":66},[],{"trials":203,"activeCount":66},[],{"trials":205,"activeCount":66},[],{"trials":207,"activeCount":66},[208],{"nctId":183,"briefTitle":184,"status":185,"phases":209,"primaryCompletion":187,"completion":187,"start":188,"enrollment":121,"conditions":210,"interventions":211},[58],[32,190,191],[170,193],{"trials":213,"activeCount":66},[],{"intervention":215,"totalTrials":62,"cells":216},"Syntocinon",{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":238},{"trials":218,"activeCount":66},[],{"trials":220,"activeCount":66},[],{"trials":222,"activeCount":66},[],{"trials":224,"activeCount":66},[],{"trials":226,"activeCount":66},[227],{"nctId":228,"briefTitle":229,"status":148,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":237},"NCT02940574","Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders",[58],"2016-12","2019-12","2015-04",40,[236],"Autism Spectrum Disorders",[215],{"trials":239,"activeCount":66},[],{"intervention":241,"totalTrials":62,"cells":242},"Tenecteplase",{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":251,"NA":265},{"trials":244,"activeCount":66},[],{"trials":246,"activeCount":66},[],{"trials":248,"activeCount":66},[],{"trials":250,"activeCount":66},[],{"trials":252,"activeCount":66},[253],{"nctId":254,"briefTitle":255,"status":148,"phases":256,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":263},"NCT02777580","STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction",[58],"2022-10-13","2023-09-30","2017-08-01",609,[262],"Myocardial Infarction",[241,264],"Clopidogrel",{"trials":266,"activeCount":66},[],{"intervention":264,"totalTrials":62,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":277,"NA":283},{"trials":270,"activeCount":66},[],{"trials":272,"activeCount":66},[],{"trials":274,"activeCount":66},[],{"trials":276,"activeCount":66},[],{"trials":278,"activeCount":66},[279],{"nctId":254,"briefTitle":255,"status":148,"phases":280,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":281,"interventions":282},[58],[262],[241,264],{"trials":284,"activeCount":66},[],{"intervention":286,"totalTrials":62,"cells":287},"Prucalopride",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":308},{"trials":289,"activeCount":66},[],{"trials":291,"activeCount":66},[],{"trials":293,"activeCount":66},[],{"trials":295,"activeCount":66},[],{"trials":297,"activeCount":66},[298],{"nctId":299,"briefTitle":300,"status":148,"phases":301,"primaryCompletion":302,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT02425774","Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway",[58],"2016-02-27","2014-07",31,[306],"Postoperative Ileus",[286],{"trials":309,"activeCount":66},[],{"intervention":311,"totalTrials":62,"cells":312},"Azithromycin Dihydrate",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":334},{"trials":314,"activeCount":66},[],{"trials":316,"activeCount":66},[],{"trials":318,"activeCount":66},[],{"trials":320,"activeCount":66},[],{"trials":322,"activeCount":66},[323],{"nctId":324,"briefTitle":325,"status":148,"phases":326,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":333},"NCT01109160","Study of Azithromycin for Lymphocytic Bronchiolitis\u002FBronchitis After Lung Transplantation",[58],"2012-10","2013-07","2010-04",15,[332],"Lymphocytic Bronchi(Oli)Tis Post-lung Transplantation",[311],{"trials":335,"activeCount":66},[],{"intervention":337,"totalTrials":62,"cells":338},"D-cure",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":359},{"trials":340,"activeCount":66},[],{"trials":342,"activeCount":66},[],{"trials":344,"activeCount":66},[],{"trials":346,"activeCount":66},[],{"trials":348,"activeCount":66},[349],{"nctId":350,"briefTitle":351,"status":148,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":358},"NCT00666367","Vitamin D as Treatment for Chronic Obstructive Pulmonary Disease (COPD)",[58],"2010-06","2010-08","2008-01",182,[18],[337],{"trials":360,"activeCount":66},[],{"intervention":362,"totalTrials":62,"cells":363},"Azithromycin",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":387},{"trials":365,"activeCount":66},[],{"trials":367,"activeCount":66},[],{"trials":369,"activeCount":66},[],{"trials":371,"activeCount":66},[],{"trials":373,"activeCount":66},[374],{"nctId":375,"briefTitle":376,"status":148,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":386},"NCT01009619","Azithromycin in Bronchiolitis Obliterans Syndrome",[58],"2009-12","2005-09",83,[382,383,384,385],"Bronchiolitis Obliterans Syndrome","Graft Rejection","Lymphocytic Bronchiolitis","Respiratory Infection",[362],{"trials":388,"activeCount":66},[],{"intervention":390,"totalTrials":62,"cells":391},"Mepolizumab Injection [Nucala]",{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":413},{"trials":393,"activeCount":66},[],{"trials":395,"activeCount":66},[],{"trials":397,"activeCount":66},[],{"trials":399,"activeCount":66},[],{"trials":401,"activeCount":66},[402],{"nctId":403,"briefTitle":404,"status":148,"phases":405,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":412},"NCT04412044","Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines",[58],"2018-05-01","2019-03-01","2016-09-01",22,[411],"Asthma",[390],{"trials":414,"activeCount":66},[],{"intervention":416,"totalTrials":62,"cells":417},"amlodipine 5\u002F10 mg per day plus valsartan 160 mg\u002Fday",{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":426,"NA":439},{"trials":419,"activeCount":66},[],{"trials":421,"activeCount":66},[],{"trials":423,"activeCount":66},[],{"trials":425,"activeCount":66},[],{"trials":427,"activeCount":66},[428],{"nctId":429,"briefTitle":430,"status":148,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":437},"NCT01030458","Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial",[58],"2012-03","2010-09",183,[436],"Blood Pressure",[416,438],"hydrochlorothiazide 6.25 mg\u002Fday plus bisoprolol 5\u002F10 mg\u002Fday",{"trials":440,"activeCount":66},[],{"intervention":438,"totalTrials":62,"cells":442},{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":451,"NA":457},{"trials":444,"activeCount":66},[],{"trials":446,"activeCount":66},[],{"trials":448,"activeCount":66},[],{"trials":450,"activeCount":66},[],{"trials":452,"activeCount":66},[453],{"nctId":429,"briefTitle":430,"status":148,"phases":454,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":455,"interventions":456},[58],[436],[416,438],{"trials":458,"activeCount":66},[],{"intervention":460,"totalTrials":62,"cells":461},"Camostat",{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":483,"NA":485},{"trials":463,"activeCount":66},[],{"trials":465,"activeCount":66},[],{"trials":467,"activeCount":66},[],{"trials":469,"activeCount":66},[470],{"nctId":471,"briefTitle":472,"status":473,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":481},"NCT04730206","The DAWN Antivirals Trial for Ambulatory COVID-19 Patients","TERMINATED",[57],"2022-07-13","2021-06-15",44,[479,480],"Covid19","SARS-CoV Infection",[460,482],"Molnupiravir",{"trials":484,"activeCount":66},[],{"trials":486,"activeCount":66},[],{"intervention":482,"totalTrials":62,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":501,"NA":503},{"trials":490,"activeCount":66},[],{"trials":492,"activeCount":66},[],{"trials":494,"activeCount":66},[],{"trials":496,"activeCount":66},[497],{"nctId":471,"briefTitle":472,"status":473,"phases":498,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":499,"interventions":500},[57],[479,480],[460,482],{"trials":502,"activeCount":66},[],{"trials":504,"activeCount":66},[],{"intervention":506,"totalTrials":62,"cells":507},"anti TNFa monoclonal antibody - Infliximab",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":509,"activeCount":66},[],{"trials":511,"activeCount":66},[],{"trials":513,"activeCount":66},[514],{"nctId":515,"briefTitle":516,"status":148,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":121,"conditions":521,"interventions":523},"NCT00604864","Effect of Anti TNFa Upon Deep Endometriosis Associated Pain",[56],"2005-02","2005-11","2004-02",[522],"Endometriosis",[506],{"trials":525,"activeCount":66},[],{"trials":527,"activeCount":66},[],{"trials":529,"activeCount":66},[],{"intervention":531,"totalTrials":62,"cells":532},"intensive insulin therapy to maintain normoglycemia",{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":534,"activeCount":66},[],{"trials":536,"activeCount":66},[],{"trials":538,"activeCount":66},[539],{"nctId":540,"briefTitle":541,"status":148,"phases":542,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":547},"NCT00115479","KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients",[56],"2005-06","2002-03",1200,[30],[531],{"trials":549,"activeCount":66},[],{"trials":551,"activeCount":66},[],{"trials":553,"activeCount":66},[],{"intervention":555,"totalTrials":62,"cells":556},"Clioquinol",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":558,"activeCount":66},[],{"trials":560,"activeCount":66},[],{"trials":562,"activeCount":66},[563],{"nctId":564,"briefTitle":565,"status":185,"phases":566,"primaryCompletion":567,"completion":567,"start":568,"enrollment":28,"conditions":569,"interventions":571},"NCT05727943","Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study",[56],"2023-12-31","2022-03-01",[570],"Epilepsy Intractable",[555],{"trials":573,"activeCount":66},[],{"trials":575,"activeCount":66},[],{"trials":577,"activeCount":66},[],{"intervention":579,"totalTrials":62,"cells":580},"Active treatment with nitrendipine (10-40 mg\u002Fday).",{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":597,"PHASE4":599,"NA":601},{"trials":582,"activeCount":66},[],{"trials":584,"activeCount":66},[],{"trials":586,"activeCount":66},[587],{"nctId":588,"briefTitle":589,"status":473,"phases":590,"primaryCompletion":591,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":596},"NCT02088450","Systolic Hypertension in Europe Placebo-Controlled Trial",[56],"1997-02","1990-02",4695,[595],"Isolated Systolic Hypertension",[579],{"trials":598,"activeCount":66},[],{"trials":600,"activeCount":66},[],{"trials":602,"activeCount":66},[],{"intervention":604,"totalTrials":62,"cells":605},"Fenfluramine",{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":607,"activeCount":66},[],{"trials":609,"activeCount":66},[],{"trials":611,"activeCount":66},[612],{"nctId":613,"briefTitle":614,"status":185,"phases":615,"primaryCompletion":616,"completion":617,"start":618,"enrollment":22,"conditions":619,"interventions":622},"NCT02655198","Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy",[56],"2018-09","2024-12","2016-01",[620,621],"Epilepsy","Lennox Gastaut Syndrome",[604],{"trials":624,"activeCount":66},[],{"trials":626,"activeCount":66},[],{"trials":628,"activeCount":66},[],{"intervention":630,"totalTrials":36,"cells":631},"Oxytocin",{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":645,"PHASE3":662,"PHASE4":674,"NA":685},{"trials":633,"activeCount":66},[],{"trials":635,"activeCount":66},[636],{"nctId":637,"briefTitle":638,"status":148,"phases":639,"primaryCompletion":640,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":644},"NCT03255148","Influence of Oxytocin on Resting State Neurophysiological Measures",[55],"2018-05-18","2017-07-24",56,[630],[630],{"trials":646,"activeCount":66},[647,653],{"nctId":648,"briefTitle":649,"status":148,"phases":650,"primaryCompletion":640,"completion":640,"start":641,"enrollment":642,"conditions":651,"interventions":652},"NCT03272321","Influence of Oxytocin on Neurophysiological Responses to Live Faces",[55,56],[630],[630],{"nctId":654,"briefTitle":655,"status":148,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":304,"conditions":660,"interventions":661},"NCT03096249","The Influence of Oxytocin on Socio-communicative Sensitivity",[55,56],"2017-05-30","2017-07-30","2016-11-21",[630],[630],{"trials":663,"activeCount":66},[664],{"nctId":665,"briefTitle":666,"status":148,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},"NCT03640156","Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin",[57],"2019-12-19","2018-07-26",25,[672],"Autism Spectrum Disorder",[630],{"trials":675,"activeCount":66},[676],{"nctId":677,"briefTitle":678,"status":148,"phases":679,"primaryCompletion":680,"completion":231,"start":618,"enrollment":681,"conditions":682,"interventions":684},"NCT03010670","Oxytocin and Interpersonal Motor Resonance",[58],"2016-08",27,[683],"Social Behavior",[630],{"trials":686,"activeCount":66},[687],{"nctId":688,"briefTitle":689,"status":148,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":696},"NCT04443647","Influence of Oxytocin on Approach-avoidance Tendencies to Social and Non-social Stimuli",[59],"2020-01-30","2018-12-15",64,[695],"Basic Science",[630],{"intervention":698,"totalTrials":62,"cells":699},"Haloperidol, azi\u002Fclari\u002Ferythromycin, levo\u002Fmoxifloxacin, co-trimoxazole, vori\u002Fketo\u002Fflu\u002Fitraconazole, methadone, tacrolimus, sunitinib",{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":706,"PHASE4":708,"NA":710},{"trials":701,"activeCount":66},[],{"trials":703,"activeCount":66},[],{"trials":705,"activeCount":66},[],{"trials":707,"activeCount":66},[],{"trials":709,"activeCount":66},[],{"trials":711,"activeCount":66},[712],{"nctId":713,"briefTitle":714,"status":148,"phases":715,"primaryCompletion":716,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":723},"NCT02068170","Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital",[],"2015-03","2015-06","2014-02",178,[721,722],"Delirium","QT-prolongation",[698],{"intervention":725,"totalTrials":62,"cells":726},"Paromomycin Sulfate Fasted State",{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":735,"NA":737},{"trials":728,"activeCount":66},[],{"trials":730,"activeCount":66},[],{"trials":732,"activeCount":66},[],{"trials":734,"activeCount":66},[],{"trials":736,"activeCount":66},[],{"trials":738,"activeCount":66},[739],{"nctId":740,"briefTitle":741,"status":185,"phases":742,"primaryCompletion":743,"completion":744,"start":745,"enrollment":28,"conditions":746,"interventions":748},"NCT01780909","The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit",[59],"2013-12","2017-12","2013-02",[747],"Concentration-Time Profiles in Stomach & Intestine.",[725,749,750,751],"Paromomycin Sulfate Fed State","Paromomycin Sulfate w\u002F domperidone","Paromomycin Sulfate w\u002F loperamide HCl",{"intervention":749,"totalTrials":62,"cells":753},{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":755,"activeCount":66},[],{"trials":757,"activeCount":66},[],{"trials":759,"activeCount":66},[],{"trials":761,"activeCount":66},[],{"trials":763,"activeCount":66},[],{"trials":765,"activeCount":66},[766],{"nctId":740,"briefTitle":741,"status":185,"phases":767,"primaryCompletion":743,"completion":744,"start":745,"enrollment":28,"conditions":768,"interventions":769},[59],[747],[725,749,750,751],{"intervention":750,"totalTrials":62,"cells":771},{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":780,"NA":782},{"trials":773,"activeCount":66},[],{"trials":775,"activeCount":66},[],{"trials":777,"activeCount":66},[],{"trials":779,"activeCount":66},[],{"trials":781,"activeCount":66},[],{"trials":783,"activeCount":66},[784],{"nctId":740,"briefTitle":741,"status":185,"phases":785,"primaryCompletion":743,"completion":744,"start":745,"enrollment":28,"conditions":786,"interventions":787},[59],[747],[725,749,750,751],{"intervention":751,"totalTrials":62,"cells":789},{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":791,"activeCount":66},[],{"trials":793,"activeCount":66},[],{"trials":795,"activeCount":66},[],{"trials":797,"activeCount":66},[],{"trials":799,"activeCount":66},[],{"trials":801,"activeCount":66},[802],{"nctId":740,"briefTitle":741,"status":185,"phases":803,"primaryCompletion":743,"completion":744,"start":745,"enrollment":28,"conditions":804,"interventions":805},[59],[747],[725,749,750,751],{"intervention":807,"totalTrials":62,"cells":808},"sterile talc pleurodesis",{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":817,"NA":819},{"trials":810,"activeCount":66},[],{"trials":812,"activeCount":66},[],{"trials":814,"activeCount":66},[],{"trials":816,"activeCount":66},[],{"trials":818,"activeCount":66},[],{"trials":820,"activeCount":66},[821],{"nctId":822,"briefTitle":823,"status":148,"phases":824,"primaryCompletion":231,"completion":231,"start":825,"enrollment":826,"conditions":827,"interventions":829},"NCT02288065","Predictive Factors and Outcome in Medical Thoracoscopy",[],"2014-01",155,[828],"Pleuritis",[807],{"intervention":831,"totalTrials":62,"cells":832},"Diclofenac potassium 50 mg",{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":841,"NA":843},{"trials":834,"activeCount":66},[],{"trials":836,"activeCount":66},[],{"trials":838,"activeCount":66},[],{"trials":840,"activeCount":66},[],{"trials":842,"activeCount":66},[],{"trials":844,"activeCount":66},[845],{"nctId":846,"briefTitle":847,"status":185,"phases":848,"primaryCompletion":187,"completion":187,"start":743,"enrollment":28,"conditions":849,"interventions":851},"NCT02007161","Supersaturation and Precipitation of Diclofenac in the Stomach of Healthy Volunteers",[59],[850],"Supersaturation and Precipitation in the Stomach",[831],{"intervention":853,"totalTrials":62,"cells":854},"Haloperidol",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":856,"activeCount":66},[],{"trials":858,"activeCount":66},[],{"trials":860,"activeCount":66},[],{"trials":862,"activeCount":66},[],{"trials":864,"activeCount":66},[],{"trials":866,"activeCount":66},[867],{"nctId":868,"briefTitle":869,"status":148,"phases":870,"primaryCompletion":718,"completion":871,"start":328,"enrollment":872,"conditions":873,"interventions":874},"NCT02043912","Drug Interactions With Risk of QT-prolongation in a General Hospital",[],"2014-04",222,[722],[853],{"intervention":876,"totalTrials":62,"cells":877},"LABA + LAMA",{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":879,"activeCount":66},[],{"trials":881,"activeCount":66},[],{"trials":883,"activeCount":66},[],{"trials":885,"activeCount":66},[],{"trials":887,"activeCount":66},[],{"trials":889,"activeCount":66},[890],{"nctId":891,"briefTitle":892,"status":185,"phases":893,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":900},"NCT02488590","Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases",[],"2020-04","2021-07","2015-07",180,[18,411,899],"Overlap Syndrome",[876,901,902,903,904],"ICS","LABA + LAMA + ICS","LABA + ICS","other",{"intervention":901,"totalTrials":62,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":908,"activeCount":66},[],{"trials":910,"activeCount":66},[],{"trials":912,"activeCount":66},[],{"trials":914,"activeCount":66},[],{"trials":916,"activeCount":66},[],{"trials":918,"activeCount":66},[919],{"nctId":891,"briefTitle":892,"status":185,"phases":920,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":921,"interventions":922},[],[18,411,899],[876,901,902,903,904],{"intervention":902,"totalTrials":62,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":926,"activeCount":66},[],{"trials":928,"activeCount":66},[],{"trials":930,"activeCount":66},[],{"trials":932,"activeCount":66},[],{"trials":934,"activeCount":66},[],{"trials":936,"activeCount":66},[937],{"nctId":891,"briefTitle":892,"status":185,"phases":938,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":939,"interventions":940},[],[18,411,899],[876,901,902,903,904],{"intervention":903,"totalTrials":62,"cells":942},{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":953},{"trials":944,"activeCount":66},[],{"trials":946,"activeCount":66},[],{"trials":948,"activeCount":66},[],{"trials":950,"activeCount":66},[],{"trials":952,"activeCount":66},[],{"trials":954,"activeCount":66},[955],{"nctId":891,"briefTitle":892,"status":185,"phases":956,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":957,"interventions":958},[],[18,411,899],[876,901,902,903,904],{"intervention":904,"totalTrials":62,"cells":960},{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":962,"activeCount":66},[],{"trials":964,"activeCount":66},[],{"trials":966,"activeCount":66},[],{"trials":968,"activeCount":66},[],{"trials":970,"activeCount":66},[],{"trials":972,"activeCount":66},[973],{"nctId":891,"briefTitle":892,"status":185,"phases":974,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":975,"interventions":976},[],[18,411,899],[876,901,902,903,904],{"intervention":978,"totalTrials":62,"cells":979},"drugs linked with QT-prolongation",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":981,"activeCount":66},[],{"trials":983,"activeCount":66},[],{"trials":985,"activeCount":66},[],{"trials":987,"activeCount":66},[],{"trials":989,"activeCount":66},[],{"trials":991,"activeCount":66},[992],{"nctId":993,"briefTitle":994,"status":148,"phases":995,"primaryCompletion":716,"completion":716,"start":996,"enrollment":997,"conditions":998,"interventions":999},"NCT02043925","QT-prolongation in Psychiatric Hospitals",[],"2010-10",152,[722],[978],{"intervention":1001,"totalTrials":62,"cells":1002},"Ketone supplementation",{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1009,"PHASE4":1011,"NA":1013},{"trials":1004,"activeCount":66},[],{"trials":1006,"activeCount":66},[],{"trials":1008,"activeCount":66},[],{"trials":1010,"activeCount":66},[],{"trials":1012,"activeCount":66},[],{"trials":1014,"activeCount":66},[1015],{"nctId":1016,"briefTitle":1017,"status":148,"phases":1018,"primaryCompletion":1019,"completion":1020,"start":1021,"enrollment":477,"conditions":1022,"interventions":1027},"NCT04744142","Effects of Ketones on Muscle Wasting During Caloric Restriction in Lean Females",[59],"2018-12-20","2019-06-01","2018-01-01",[1023,1024,1025,1026],"Muscle Wasting","Protein Intake","Ketosis","Caloric Restriction",[1001],{"intervention":1029,"totalTrials":62,"cells":1030},"Suspension Fasted State",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1037,"PHASE4":1039,"NA":1041},{"trials":1032,"activeCount":66},[],{"trials":1034,"activeCount":66},[],{"trials":1036,"activeCount":66},[],{"trials":1038,"activeCount":66},[],{"trials":1040,"activeCount":66},[],{"trials":1042,"activeCount":66},[1043],{"nctId":1044,"briefTitle":1045,"status":185,"phases":1046,"primaryCompletion":187,"start":825,"enrollment":28,"conditions":1047,"interventions":1048},"NCT02048345","Gastrointestinal Behavior of Posaconazol in Healthy Volunteers",[59],[24],[1029,1049,1050,1051],"Suspension Fed State","Solution Fasted State","Solution Fed State",{"intervention":1049,"totalTrials":62,"cells":1053},{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1055,"activeCount":66},[],{"trials":1057,"activeCount":66},[],{"trials":1059,"activeCount":66},[],{"trials":1061,"activeCount":66},[],{"trials":1063,"activeCount":66},[],{"trials":1065,"activeCount":66},[1066],{"nctId":1044,"briefTitle":1045,"status":185,"phases":1067,"primaryCompletion":187,"start":825,"enrollment":28,"conditions":1068,"interventions":1069},[59],[24],[1029,1049,1050,1051],{"intervention":1050,"totalTrials":62,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1073,"activeCount":66},[],{"trials":1075,"activeCount":66},[],{"trials":1077,"activeCount":66},[],{"trials":1079,"activeCount":66},[],{"trials":1081,"activeCount":66},[],{"trials":1083,"activeCount":66},[1084],{"nctId":1044,"briefTitle":1045,"status":185,"phases":1085,"primaryCompletion":187,"start":825,"enrollment":28,"conditions":1086,"interventions":1087},[59],[24],[1029,1049,1050,1051],{"intervention":1051,"totalTrials":62,"cells":1089},{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1096,"PHASE4":1098,"NA":1100},{"trials":1091,"activeCount":66},[],{"trials":1093,"activeCount":66},[],{"trials":1095,"activeCount":66},[],{"trials":1097,"activeCount":66},[],{"trials":1099,"activeCount":66},[],{"trials":1101,"activeCount":66},[1102],{"nctId":1044,"briefTitle":1045,"status":185,"phases":1103,"primaryCompletion":187,"start":825,"enrollment":28,"conditions":1104,"interventions":1105},[59],[24],[1029,1049,1050,1051],{"intervention":1107,"totalTrials":62,"cells":1108},"Medication use during pregnancy",{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1110,"activeCount":66},[],{"trials":1112,"activeCount":66},[],{"trials":1114,"activeCount":66},[],{"trials":1116,"activeCount":66},[],{"trials":1118,"activeCount":66},[],{"trials":1120,"activeCount":66},[1121],{"nctId":1122,"briefTitle":1123,"status":148,"phases":1124,"primaryCompletion":1125,"completion":1126,"start":231,"enrollment":1127,"conditions":1128,"interventions":1131},"NCT03105583","A Cross-sectional Study Evaluating Pregnancy Related Use of Vitamins and Medication",[],"2017-04","2018-01",381,[1129,1130],"Medication and Supplement Use","Pregnant Women",[1107]]